GTG Genetic Technologies Limited

By Denny Jacob

International stocks trading in New York closed mixed on Friday.

The S&P/BNY Mellon index of American depositary receipts ticked down 0.1% to 155.61. The European index edged up 0.6% to 145.11. The Asian index lost 1.4% to 186.11. The Latin American index moved up 0.7% to 227.71, while the emerging-markets index retreated 1.1% to 320.30.

Adaptimmune Therapeutics Plc was among those whose ADRs traded actively.

The novel cancer immunotherapy products developer fell 2.7% after it said Friday that data from multiple solid tumor indications confirms that MAGE-A4 is a broadly expressed cancer target for SPEAR T-cell therapy.

Molecular diagnostics company Genetic Technologies moved down 3.8% after it provided its year to date results for the nine months ended March 31, noting that its product geneType Multi-Risk Test received approval for commercial release and that the U.S. Patent and Trademark Office granted a patent for the geneType Covid-19 Risk Test.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

April 08, 2022 16:25 ET (20:25 GMT)

Genetic Technologies (ASX:GTG)
Historical Stock Chart
From Nov 2024 to Dec 2024

Genetic Technologies (ASX:GTG)
Historical Stock Chart
From Dec 2023 to Dec 2024